Xu, C-F <br/><br/>
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.  [electronic resource] 

 -  British journal of cancer  Apr 2010 
 - 1371-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/sj.bjc.6605653  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Alanine Transaminase--metabolism<br/>Antineoplastic Agents--adverse effects<br/>Bilirubin--metabolism<br/>Carcinoma, Renal Cell--drug therapy<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>Female<br/>Genotype<br/>Gilbert Disease--genetics<br/>Glucuronosyltransferase--antagonists & inhibitors<br/>Humans<br/>Hyperbilirubinemia--chemically induced<br/>Indazoles<br/>Kidney Neoplasms--drug therapy<br/>Liver--enzymology<br/>Male<br/>Middle Aged<br/>Nephrectomy<br/>Polymorphism, Genetic<br/>Pyrimidines--adverse effects<br/>Sulfonamides--adverse effects